                            NIH Public Access
                            Author Manuscript
                            J Neurosci. Author manuscript; available PMC 2013 October 10.
                           Published final edited form 
NIH-PA Author Manuscript




                            J Neurosci. 2013 April 10; 33(15): 6557–6562. doi:10.1523/JNEUROSCI.1536-12.2013.



                           neuroprotective drug riluzole acts small conductance
                           Ca2+-activated K+ channels ameliorate defects Spinal
                           Muscular Atrophy models
                           Maria Dimitriadi1, Min Jeong Kye2,3, Geetika Kalloo1, Jill M. Yersak1, Mustafa Sahin2,                            Anne C. Hart1
                           1Department Neuroscience, Brown University, Providence, RI 02912, USA

                           2The F.M. Kirby Neurobiology Center, Department Neurology, Children’s Hospital Boston,
                           Harvard Medical School, Boston, MA 02115, USA
                           3Institute   Human Genetics, University Cologne, Cologne, D-50931, Germany

                           Abstract
NIH-PA Author Manuscript




                                Spinal muscular atrophy (SMA), recessive neuromuscular disorder, caused diminished
                                function Survival Motor Neuron (SMN) protein. define cellular processes pertinent
                                SMA, parallel genetic screens undertaken Drosophila C. elegans SMA models                                 identify modifiers SMN loss function phenotypes. class genetic modifiers
                                small conductance, Ca2+-activated K+ (SK) channels. SK channels allow efflux                                 potassium ions intracellular calcium increases activated neuroprotective
                                drug riluzole. drug proven, albeit modest, efficacy treatment                                 Amyotrophic Lateral Sclerosis (ALS). unclear riluzole extend lifespan ameliorate
                                symptoms SMA patients previous studies limited insufficient power draw                                 conclusions. critical biochemical target riluzole motorneuron disease known,                                 pharmacological targets riluzole include SK channels. examine impact                                 riluzole different SMA models. vertebrate neurons, riluzole treatment restored axon
                                outgrowth caused diminished SMN. Additionally, riluzole ameliorated neuromuscular
                                defects C. elegans SMA model SK channel function required beneficial
                                effect. propose riluzole improves motorneuron function acting SK channels                                 suggest SK channels important therapeutic targets SMA patients.
NIH-PA Author Manuscript




                           Introduction
                                            Spinal Muscular Atrophy (SMA), autosomal recessive neuromuscular disorder,                                             leading genetic cause infant death United States (Crawford & Pardo, 1996; Pearn,
                                            1978). SMA primarily affects α-motorneurons anterior horn spinal cord                                             characterized progressive muscle degeneration, loss neuromuscular function,
                                            paralysis death. SMA caused Survival Motor Neuron 1 (SMN1) homozygous
                                            loss function mutations lead decreased Survival Motor Neuron (SMN) protein
                                            levels (Lefebvre et al., 1995). Amyotrophic Lateral Sclerosis (ALS) commonalities                                             SMA target spinal cord motorneurons share phenotypic, genetic molecular
                                            similarities. example, SMN gene variants associated sporadic ALS
                                            (Blauw et al., 2012; Corcia et al., 2009; Veldink et al., 2001), expression TDP-43,                                             ALS protein, increases SMN mRNA levels (Bose et al., 2008), mutation vesicle-


                           Corresponding author: Anne C. Hart, Brown University, 185 Meeting Street, Mailbox GL-N, Providence, RI 02912,
                           anne_hart@brown.edu.
                            Dimitriadi et al.                                                                                              Page 2


                                               trafficking protein VAPB cause late-onset SMA ALS (Nishimura et al., 2004).
                                                neuromuscular disorders share common neurodegenerative pathway
                                               respond similar treatments.
NIH-PA Author Manuscript




                                               previously reported small conductance Ca2+-activated K+ (SK) channels                                                cross-species invertebrate SMN modifiers (Chang et al., 2008; Dimitriadi et al., 2010). SK
                                               channels activated intracellular calcium, potassium selective,                                                implicated epilepsy, ataxias disorders (Pedarzani & Stocker, 2008), play
                                               roles hyperpolarization, repetitive firing, dendritic integration, synaptic transmission
                                               synaptic plasticity (Keen et al., 1999; Schumacher et al., 2001; Xia et al., 1998).                                                neurons, SK channel activity regulated calcium entry voltage-gated calcium
                                               channels. overall impact SK channels neuronal activity difficult predict.
                                               Increased potassium efflux reduce excitability, coupled depolarization-
                                               induced calcium influx, SK channels increase firing rates accelerating repolarization.
                                               SK2 channels complex L-type Ca2+ channels α-actinin,                                                actin-binding protein (Lu et al., 2009; Lu et al., 2007). α-actinin interacts directly SMN
                                               Drosophila adult muscle (Rajendra et al., 2007), α-actinin orthologs invertebrate
                                               SMN modifier genes (Chang et al., 2008; Dimitriadi et al., 2010).

                                               SK channels pharmacological targets riluzole. Riluzole ameliorates                                                aberrant cytoskeletal organization synaptic terminals mice lacking SMN exon 7
NIH-PA Author Manuscript




                                               (Haddad et al., 2003). Riluzole impact severely affected SMA patients short
                                               duration study limited number subjects (Russman et al., 2003). study                                                insufficient power determine riluzole benefit SMA patient populations.
                                               Elucidating biochemical target riluzole increase understanding ALS                                                SMA pathogenesis.  test hypothesis riluzole ameliorate SMN loss                                                function defects species.

                               Materials Methods
                               C. elegans strains
                                               LM99 smn-1(ok355 hT2  III) (Briese et al., 2009), HA2207 kcnl-2(tm1885)
                                               smn-1(ok355)/hT2, HA2415 kcnl-2(ok2818) smn-1(ok355)/hT2, HA2400 smn-1(ok355)/
                                               hT2; slo-1(js118)V, HA2402 smn-1(ok355)/hT2; slo-2(nf100)X, HA2404 smn-1(ok355)/
                                               hT2; sup-9(n180)II strains cultivated 20°C standard conditions (Brenner,
                                               1974). kcnl-2 alleles tm1885 ok2818 backcrossed times, respectively.
                                               tm1885 removes transmembrane domains; ok2818 perturbs transmembrane domains
                                               calmodulin-binding domain. kcnl-2(tm1885) pumping rates slightly lower                                                kcnl-2(ok2818) (p=3×10−4). assays used progeny hT2 parents control genetic
NIH-PA Author Manuscript




                                               background.

                               C. elegans assays
                                               pharyngeal pumping assay performed previously described (Dimitriadi et al.,
                                               2010). Eggs hatched L4440 control vector (Kamath & Ahringer, 2003) reared                                                days 25°C day 20°C. Pumping rates determined larval
                                               stage. Average pumping rates (± standard error mean, SEM) derived                                                independent trials (n≥ 25 animals total). Experimenters blinded                                                genotype/treatment trial. Figure 2A 2C, independent
                                               trials performed pooled final figure. Unpooled results Figure
                                               2A: Trials 1–3 Control/DMSO 302±7, Control/3μM 266±17, Control/33μM 242±12,
                                               Cesmn-1/DMSO 23±5, Cesmn-1/3μM 59±14, Cesmn-1/33μM 70±13; Cesmn-1/DMSO vs
                                               Cesmn-1/3μM p=0.04 & Cesmn-1/DMSO vs Cesmn-1/33uM p=0.007; Trials 4–5 Control/


                                                    J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                        Page 3


                                               DMSO 268±9, Control/1μM 257±9, Cesmn-1/DMSO 48±11, Cesmn-1/1μM 38±11.
                                               Unpooled results Figure 2C: Trials 1–4 Control 244±6, kcnl-2(tm1885) 194±13, Cesmn-1
                                               57±10, kcnl-2(tm1885) Cesmn-1 24±8; p=0.01 Cesmn-1 vs kcnl-2(tm1885) Cesmn-1; Trials
NIH-PA Author Manuscript




                                               5–7 Control 238±7, kcnl-2(ok2818) 210±12, Cesmn-1 74±14, kcnl-2(ok2818) Cesmn-1
                                               36±10; p=0.01 Cesmn-1 vs kcnl-2(ok2818) Cesmn-1; Trials 8–10 Control 224±9, slo-1
                                               195±13, slo-2 217±11, sup-9 238±11, Cesmn-1 47±11, Cesmn-1;slo-1 51±8, Cesmn-1;slo-2
                                               74±11, Cesmn-1;sup-9 62±11; p=0.04 Cesmn-1 vs Cesmn-1;slo-2. motility assay                                                described previously (Briese et al., 2009).  C. elegans reared plates                                                days 25°C day 20°C. Motility assessed manually 2 min M9 buffer
                                               Day 3 post-hatching regardless developmental stage. complete bend mid-body                                                scored beat. independent trials performed.

                               Compounds
                                               Riluzole (R116) apamin (A9459) purchased Sigma-Aldrich. Riluzole
                                               dramatically decreased egg laying (data shown).

                               Hippocampal cell culture
                                               Experimental procedures performed compliance animal protocols approved                                                Children’s Hospital IACUC, Boston. Hippocampi dissected E18 Sprague-Dawley
                                               rat embryos (Charles River). Neurons dissociated papain, triturated, plated
NIH-PA Author Manuscript




                                               poly-D-Lysine/Laminin (Sigma/Invitrogen) coated plates 250,000 cells/6                                                culture plates Western blotting 20,000 cells/24 culture plates                                                immunostaining. Neurons cultured Neurobasal medium B27 supplement
                                               (Invitrogen), 500μM L-glutamine (Invitrogen), 1x penicillin/streptomycin (Invitrogen)                                                37°C humidified incubator 5  CO2.

                               Inhibition SMN, riluzole treatment measurement neuronal morphology SMN
                                               knocked using conventional siRNA technique, (Applied Biosystems),
                                               Lipofectamine 2000 (Invitrogen), Opti-MEM (Invitrogen). Briefly, neurons                                                transiently transfected siRNA treated riluzole DMSO 24 hours.                                                days post-transfection, protein lysates collected; SMN (BD Biosciences)                                                synaptophysin (Cell Signaling) protein levels measured Western using GAPDH
                                               (Life Technologies) control. immunohistology, neurons fixed 4 
                                               paraformaldehyde stained Tau antibody (Millipore) (Choi et al., 2008). Length                                                Tau-positive axons measured using ImageJ.

                               Statistical analysis
NIH-PA Author Manuscript




                                               Significance determined Mann-Whitney U  tailed) way ANOVA.                                                ANOVA, paired t-tests used identify significantly different pairs. Corresponding p
                                               F values reported.

                               Results
                               Riluzole prevents axonal defects vertebrate neurons
                                               examined impact riluzole rat embryonic hippocampal neurons reduced
                                               SMN levels. SMN knockdown reduced axon outgrowth neurons based overall
                                               process length (p=6.7×10−5). Treatment 10nM 50nM riluzole increased control                                                restored SMN-deficient axons comparable levels (Figure 1A & 1B). Longest axon length
                                               significantly reduced SMN knockdown (p=1.4×10−5), restored wild
                                               type levels riluzole treatment (Figure 1C). Riluzole does ameliorate SMN
                                               knockdown defects increasing SMN protein levels; riluzole treatment actually decreased


                                                    J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                            Page 4


                                               SMN protein levels control SMN deficient neurons (Figure 1D). SMN protein
                                               levels tightly regulated development; expression high embryonic tissues,                                                concentration SMN decreases cells differentiate (Grice & Liu, 2011; La Bella et al.,
NIH-PA Author Manuscript




                                               1998). address possibility riluzole accelerate hippocampal neuron
                                               maturation, lowering SMN, examined synaptophysin levels  normally
                                               increase hippocampal neurons mature culture) (Daly & Ziff, 1997). Riluzole raised
                                               synaptophysin levels consistent accelerated maturation (Figure 1E).                                                 riluzole neuroprotection increased SMN levels, riluzole accelerate
                                               neuronal maturation.

                               Riluzole ameliorates SMN loss function defects C. elegans
                                               address mechanism riluzole protection, turned Caenorhabditis elegans
                                               SMA model. C. elegans genome harbors single ortholog SMN, smn-1, referred                                                Cesmn-1 clarity. Complete loss Cesmn-1 causes slow growth, larval lethality
                                               impairs neuromuscular function locomotion pharyngeal pumping                                                feeding (Briese et al, 2009; Dimitriadi et al., 2010). C. elegans feed microorganisms
                                               using discrete subset muscles neurons pharynx (Avery, 1993). Animals pump
                                               continuously 250 beats minute food. pumping rates SMN loss                                                function animals (Cesmn-1(lf)) significantly reduced; defects progressive                                                developmental defect. Cesmn-1(lf) recessive heterozygous animals overtly
                                               normal (Briese et al, 2009; Dimitriadi et al., 2010). assess impact riluzole, control
NIH-PA Author Manuscript




                                               Cesmn-1(lf) animals reared plates containing drug. Riluzole partially
                                               rescued SMN loss function defects treatment increased Cesmn-1(lf) pharyngeal
                                               pumping rates (p=0.044 3μM, p=0.004 33μM, Figure 2A). contrast, riluzole
                                               lowered pumping rates controls, (p=0.027 1μM, p=0.001 33μM) suggesting
                                               riluzole beneficial neuromuscular function perturbed. efficacy                                                riluzole tested using motility, neuromuscular assay measures frequency
                                               body bends swimming (Briese et al., 2009). Riluzole significantly increased                                                Cesmn-1(lf) motility (p=0.04 333M, Figure 2D) consistent riluzole ameliorating
                                               Cesmn-1 loss function neuromuscular defects.

                               Riluzole likely acts SK channels
                                               tested hypothesis riluzole acts SK channels ameliorate defects using C.
                                               elegans.  SK channels blocked pharmacologically. Application SK2/SK3
                                               channel blocker apamin exacerbated Cesmn-1(lf) pumping defects, suggesting blocking
                                               SK channels impairs Cesmn-1(lf) neuromuscular function (Figure 2B). Second, SK
                                               channels tested using genetic tools. Previously, RNAi knockdown C. elegans SK
                                               channel ortholog (kcnl-2) enhanced Cesmn-1(lf) growth defects ameliorated NIH-PA Author Manuscript




                                               pumping defects (Dimitriadi et al., 2010). RNAi target effects RNAi                                                feeding inefficient C. elegans neurons, used C. elegans kcnl-2 alleles
                                               (kcnl-2(tm1885) kcnl-2(ok2818)) likely cause complete loss function,                                                accurately assess impact kcnl-2 loss Cesmn-1. Pumping rates kcnl-2(tm1885)
                                               Cesmn-1(lf) kcnl-2(ok2818) Cesmn-1(lf) double mutant animals significantly
                                               decreased (p=0.003 & p=0.023, respectively, Figure 2C). riluzole activates SK channels                                                ameliorate SMN loss function defects, loss kcnl-2 abrogate beneficial
                                               effects riluzole. Consistent hypothesis, riluzole treatment did increase                                                pumping rates kcnl-2 Cesmn-1(lf) mutant animals (Figure 2C tm1885; data shown
                                               ok2818).  riluzole requires kcnl-2 SK channel function ameliorate SMN
                                               loss function neuromuscular defects. confirmed assay. kcnl-2(tm1885)
                                               Cesmn-1(lf) animals decreased motility swimming compared controls
                                               (p=0.029 & p=0.007, respectively). Loss kcnl-2 exacerbated motility defects                                                Cesmn-1(lf) (p=0.001), riluzole treatment did benefit kcnl-2 Cesmn-1(lf) mutant


                                                    J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                             Page 5


                                               animals (Figure 2D tm1885; data shown ok2818). address specificity kcnl-2,
                                               potassium channels examined. Loss slo-1(js118), slo-2(nf100) sup-9(n180)
                                               did exacerbate Cesmn-1(lf) pumping defects, suggesting riluzole requires kcnl-2 SK
NIH-PA Author Manuscript




                                               channels ameliorate SMN loss function neuromuscular defects.

                               Discussion
                                               early observations abnormal glutamate metabolism decreased glutamate
                                               transport brain spinal cord ALS patients led hypothesis                                                excitatory amino acid neurotransmitter glutamate involved ALS pathogenesis
                                               (Plaitakis, 1991; Rothstein et al., 1992).  drugs affecting glutamatergic                                                suggested putative therapeutic agents. Riluzole initially identified paralytic
                                               agent (Domino et al., 1952) later shown indirectly modulate glutamatergic
                                               transmission (Albo et al., 2004; Benavides et al., 1985; Debono et al., 1993; Doble et al.,
                                               1992). subsequently significantly improve muscle strength disease
                                               progression ALS patients (Bensimon et al., 1994; Lacomblez et al., 1996).                                                mechanism riluzole protection remains unclear (Bellingham, 2011; Kuo et al., 2005;
                                               Schuster et al., 2012), riluzole diverse direct targets. include potassium
                                               channels: SK channels (Cao et al., 2002; Grunnet et al., 2001), large conductance Ca2+-
                                               activated BK channels (Wang et al., 2008; Wu & Li, 1999), TREK-1 TRAAK 
                                               pore-domain channels (Duprat et al., 2000; Fink et al., 1998).  riluzole blocks voltage-
NIH-PA Author Manuscript




                                               dependent sodium channels (Benoit & Escande, 1991; Song et al., 1997; Zona et al., 1998)
                                               voltage-gated N- P/Q-type calcium channels (Huang et al., 1997). Additionally,
                                               riluzole inhibit cholinergic receptors (Deflorio et al., 2012) decrease protein kinase
                                               C (PKC) activity (Noh et al., 2000).

                                               SK channels identified previously cross-species genetic modifiers invertebrate
                                               SMA models (Chang et al., 2008; Dimitriadi et al., 2010).  provide evidence                                                riluzole beneficial effects SMA models act SK channels. Loss                                                C. elegans SK channel ortholog kcnl-2 exacerbated Cesmn-1(lf) neuromuscular defects.
                                               Apamin, blocks SK2 SK3 channels, exacerbated Cesmn-1 loss function
                                               defects. Treatment riluzole, actions include SK channel activation, improved                                                neuromuscular function Cesmn-1(lf) animals axon outgrowth SMN deprived
                                               rat hippocampal neurons.

                                               Franks workers identified sodium current pharyngeal muscles                                                sensitive sodium channel drugs (Franks et al., 2002), genes mRNAs encoding
                                               classical voltage-gated sodium channels C. elegans, suggesting                                                riluzole likely does act channels ameliorate Cesmn-1(lf) defects. Riluzole
NIH-PA Author Manuscript




                                               restored axon outgrowth caused diminished SMN vertebrate neurons. Apamin,
                                               blocks classes SK channels, impact hippocampal neurons (data                                                shown), suggesting apamin-sensitive SK channels expressed stage
                                               beneficial effects riluzole solely SK channels mammalian
                                               neurons.

                                               present study reports riluzole, beneficial, does increase SMN protein
                                               levels.  riluzole treatment increased levels hippocampal neuron maturation
                                               marker, synaptophysin, suggesting riluzole accelerate maturation consequent
                                               decreases SMN levels.  worthwhile investigate synergistic
                                               effects riluzole combination drugs directly increase SMN levels (Wadman et
                                               al., 2011a; Wadman et al., 2011b). summary, studies demonstrate beneficial
                                               impact riluzole SMA models suggest riluzole acts SK channels 


                                                    J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                                              Page 6


                                               ameliorate SMN loss function defects, delineating important therapeutic pathway                                                neuromuscular disease patients.
NIH-PA Author Manuscript




                               Acknowledgments
                                               work supported funding SMA Foundation NIH NINDS (NS066888) C.H, Slaney
                                               Family Fund Children’s Hospital Boston Translational Research Program M.S., Children’s Hospital
                                               Boston Mental Retardation Developmental Disabilities Research Center (P30 HD18655). M.K. supported                                                fellowship William Hearst Foundation. nematode strains used work provided                                                Caenorhabditis Genetics Center, funded NIH National Center Research Resources. Helpful
                                               discussions Drs. Spyros Artavanis-Tsakonas, David Van Vactor, Lee Rubin, Diane Lipscombe, members
                                               laboratories invaluable. grateful C. elegans knockout consortia Japanese National
                                               BioResource Project reagents, Luis Miguel Briseno help measurement neuronal morphology
                                               Dr. George Poulogiannis statistical analysis.


                               References
                                               Albo F, Pieri M, Zona C. Modulation AMPA receptors spinal motorneurons                                                  neuroprotective agent riluzole. J Neurosci Res. 2004; 78:200–7. [PubMed: 15378511]
                                               Avery L. genetics feeding Caenorhabditis elegans. Genetics. 1993; 133:897–917. [PubMed:
                                                 8462849]
                                               Bellingham MC. review neural mechanisms action clinical efficiency riluzole                                                  treating amyotrophic lateral sclerosis: learned decade? CNS Neurosci Ther.
NIH-PA Author Manuscript




                                                 2011; 17:4–31. [PubMed: 20236142]
                                               Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan  Legrand JJ, Gueremy C, Le Fur G. 2-
                                                 Amino-6-trifluoromethoxy benzothiazole, possible antagonist excitatory amino acid
                                                 neurotransmission--II. Biochemical properties. Neuropharmacology. 1985; 24:1085–92. [PubMed:
                                                 3001571]
                                               Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels myelinated nerve fibre.
                                                 Pflugers Arch. 1991; 419:603–9. [PubMed: 1664937]
                                               Bensimon G, Lacomblez L, Meininger V. controlled trial riluzole amyotrophic lateral sclerosis.
                                                 ALS/Riluzole Study Group. N Engl J Med. 1994; 330:585–91. [PubMed: 8302340]
                                               Blauw HM, Barnes CP, van Vught PW, van Rheenen W, Verheul M, Cuppen E, Veldink JH, van den
                                                 Berg LH. SMN1 gene duplications associated sporadic ALS. Neurology. 2012; 78:776–80.
                                                 [PubMed: 22323753]
                                               Bose JK, Wang  Hung L, Tarn WY, Shen CK. TDP-43 overexpression enhances exon 7 inclusion
                                                 survival motor neuron pre-mRNA splicing. J Biol Chem. 2008; 283:28852–9.
                                                 [PubMed: 18703504]
                                               Brenner S. genetics Caenorhabditis elegans. Genetics. 1974; 77:71–94. [PubMed: 4366476]
                                               Briese M, Esmaeili B, Fraboulet S, Burt EC, Christodoulou S, Towers PR, Davies KE, Sattelle DB.
                                                   Deletion smn-1, Caenorhabditis elegans ortholog spinal muscular atrophy gene,
NIH-PA Author Manuscript




                                                   results locomotor dysfunction reduced lifespan. Hum Mol Genet. 2009; 18:97–104.
                                                   [PubMed: 18829666]
                                               Cao YJ, Dreixler JC, Couey JJ, Houamed KM. Modulation recombinant native neuronal SK
                                                   channels neuroprotective drug riluzole. Eur J Pharmacol. 2002; 449:47–54. [PubMed:
                                                   12163105]
                                               Chang HC, Dimlich DN, Yokokura T, Mukherjee  Kankel MW, Sen  Sridhar V, Fulga TA, Hart
                                                   AC, Van Vactor D, Artavanis-Tsakonas S. Modeling spinal muscular atrophy Drosophila. PLoS
                                                    2008; 3:e3209. [PubMed: 18791638]
                                               Choi YJ, Di Nardo  Kramvis  Meikle L, Kwiatkowski DJ, Sahin M, X. Tuberous sclerosis
                                                   complex proteins control axon formation. Genes Dev. 2008; 22:2485–95. [PubMed: 18794346]
                                               Corcia P, Camu W, Praline J, Gordon PH, Vourch P, Andres C. importance SMN genes                                                    genetics sporadic ALS. Amyotroph Lateral Scler. 2009; 10:436–40. [PubMed: 19922137]
                                               Crawford  Pardo CA. neurobiology childhood spinal muscular atrophy. Neurobiol Dis.
                                                   1996; 3:97–110. [PubMed: 9173917]



                                                     J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                                   Page 7


                                               Daly C, Ziff EB. Post-transcriptional regulation synaptic vesicle protein expression                                                    developmental control synaptic vesicle formation. J Neurosci. 1997; 17:2365–75. [PubMed:
                                                   9065497]
NIH-PA Author Manuscript




                                               Debono MW, Le Guern J, Canton T, Doble  Pradier L. Inhibition riluzole electrophysiological
                                                   responses mediated rat kainate NMDA receptors expressed Xenopus oocytes. Eur J
                                                   Pharmacol. 1993; 235:283–9. [PubMed: 7685290]
                                               Deflorio C, Palma E, Conti L, Roseti C, Manteca  Giacomelli E, Catalano M, Limatola C, Inghilleri
                                                   M, Grassi F. Riluzole Blocks Human Muscle Acetylcholine Receptors. J Physiol. 2012; 590:2519–
                                                   28. [PubMed: 22431338]
                                               Dimitriadi M, Sleigh JN, Walker  Chang HC, Sen  Kalloo G, Harris J, Barsby T, Walsh MB,
                                                   Satterlee JS, Li C, Van Vactor D, Artavanis-Tsakonas S, Hart AC. Conserved genes act                                                    modifiers invertebrate SMN loss function defects. PLoS Genet. 2010; 6:e1001172. [PubMed:
                                                   21124729]
                                               Doble  Hubert JP, Blanchard JC. Pertussis toxin pretreatment abolishes inhibitory effect                                                    riluzole carbachol D-[3H]aspartate release cultured cerebellar granule cells. Neurosci
                                                   Lett. 1992; 140:251–4. [PubMed: 1354343]
                                               Domino EF, Unna KR, Kerwin J. Pharmacological properties benzazoles.  Relationship                                                    structure paralyzing action. J Pharmacol Exp Ther. 1952; 105:486–97. [PubMed: 14955779]
                                               Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M. neuroprotective agent riluzole
                                                   activates P domain K(+) channels TREK-1 TRAAK. Mol Pharmacol. 2000; 57:906–
                                                   12. [PubMed: 10779373]
NIH-PA Author Manuscript




                                               Fink M, Lesage F, Duprat F, Heurteaux C, Reyes R, Fosset M, Lazdunski M. neuronal P
                                                   domain K+ channel stimulated arachidonic acid polyunsaturated fatty acids. EMBO J.
                                                   1998; 17:3297–308. [PubMed: 9628867]
                                               Franks CJ, Pemberton D, Vinogradova  Cook  Walker RJ, Holden-Dye L. Ionic basis resting
                                                   membrane potential action potential pharyngeal muscle Caenorhabditis elegans. J
                                                   Neurophysiol. 2002; 87:954–61. [PubMed: 11826060]
                                               Grice SJ, Liu JL. Survival motor neuron protein regulates stem cell division, proliferation,                                                    differentiation Drosophila. PLoS Genet. 7:e1002030. [PubMed: 21490958]
                                               Grunnet M, Jespersen T, Angelo K, Frokjaer-Jensen C, Klaerke DA, Olesen SP, Jensen BS.
                                                   Pharmacological modulation SK3 channels. Neuropharmacology. 2001; 40:879–87. [PubMed:
                                                   11378158]
                                               Haddad H, Cifuentes-Diaz C, Miroglio  Roblot N, Joshi V, Melki J. Riluzole attenuates spinal
                                                   muscular atrophy disease progression mouse model. Muscle Nerve. 2003; 28:432–7.
                                                   [PubMed: 14506714]
                                               Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T. Effects neuroprotective agent riluzole                                                    high voltage-activated calcium channels rat dorsal root ganglion neurons. J Pharmacol Exp
                                                   Ther. 1997; 282:1280–90. [PubMed: 9316836]
                                               Kamath RS, Ahringer J. Genome-wide RNAi screening Caenorhabditis elegans. Methods. 2003;
                                                   30:313–21. [PubMed: 12828945]
NIH-PA Author Manuscript




                                               Keen JE, Khawaled R, Farrens DL, Neelands T, Rivard  Bond CT, Janowsky  Fakler B, Adelman
                                                   JP, Maylie J. Domains responsible constitutive Ca(2+)-dependent interactions                                                    calmodulin small conductance Ca(2+)-activated potassium channels. J Neurosci. 1999;
                                                   19:8830–8. [PubMed: 10516302]
                                               Kuo JJ, Siddique T, Fu R, Heckman CJ. Increased persistent Na(+) current effect                                                    excitability motoneurones cultured mutant SOD1 mice. J Physiol. 2005; 563:843–54.
                                                   [PubMed: 15649979]
                                               La Bella V, Cisterni C, Salaun D, Pettmann B. Survival motor neuron (SMN) protein rat                                                    expressed different molecular forms developmentally regulated. Eur J Neurosci. 1998;
                                                   10:2913–23. [PubMed: 9758161]
                                               Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study riluzole                                                    amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet.
                                                   1996; 347:1425–31. [PubMed: 8676624]




                                                    J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                                    Page 8


                                               Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C,
                                                   Millasseau P, Zeviani M, et al. Identification characterization spinal muscular atrophy-
                                                   determining gene. Cell. 1995; 80:155–65. [PubMed: 7813012]
NIH-PA Author Manuscript




                                               Lu L, Timofeyev V, Li N, Rafizadeh S, Singapuri  Harris TR, Chiamvimonvat N. Alpha-actinin2
                                                   cytoskeletal protein required functional membrane localization Ca2+-activated K+
                                                   channel (SK2 channel). Proc Natl Acad Sci U S  2009; 106:18402–7. [PubMed: 19815520]
                                               Lu L, Zhang Q, Timofeyev V, Zhang  Young JN, Shin HS, Knowlton AA, Chiamvimonvat N.
                                                   Molecular coupling Ca2+-activated K+ channel L-type Ca2+ channels alpha-actinin2.
                                                   Circ Res. 2007; 100:112–20. [PubMed: 17110593]
                                               Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa  Middleton S, Cascio D, Kok F, Oliveira
                                                   JR, Gillingwater T, Webb J, Skehel P, Zatz M. mutation vesicle-trafficking protein VAPB
                                                   causes late-onset spinal muscular atrophy amyotrophic lateral sclerosis. J Hum Genet.
                                                   2004; 75:822–31. [PubMed: 15372378]
                                               Noh KM, Hwang JY, Shin HC, Koh JY. novel neuroprotective mechanism riluzole: direct
                                                   inhibition protein kinase C. Neurobiol Dis. 2000; 7:375–83. [PubMed: 10964608]
                                               Pearn J. Incidence, prevalence, gene frequency studies chronic childhood spinal muscular
                                                   atrophy. J Med Genet. 1978; 15:409–13. [PubMed: 745211]
                                               Pedarzani P, Stocker M. Molecular cellular basis small- intermediate-conductance,
                                                   calcium-activated potassium channel function brain. Cell Mol Life Sci. 2008; 65:3196–217.
                                                   [PubMed: 18597044]
                                               Plaitakis  Altered glutamatergic mechanisms selective motor neuron degeneration NIH-PA Author Manuscript




                                                   amyotrophic lateral sclerosis: possible role glycine. Adv Neurol. 1991; 56:319–26. [PubMed:
                                                   1677233]
                                               Rajendra TK, Gonsalvez GB, Walker MP, Shpargel KB, Salz HK, Matera AG. Drosophila
                                                   melanogaster model spinal muscular atrophy reveals function SMN striated muscle. J
                                                   Cell Biol. 2007; 176:831–41. [PubMed: 17353360]
                                               Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport brain spinal cord                                                    amyotrophic lateral sclerosis. N Engl J Med. 1992; 326:1464–8. [PubMed: 1349424]
                                               Russman BS, Iannaccone ST, Samaha FJ. phase 1 trial riluzole spinal muscular atrophy. Arch
                                                   Neurol. 2003; 60:1601–3. [PubMed: 14623733]
                                               Schumacher MA, Rivard AF, Bachinger HP, Adelman JP. Structure gating domain Ca2+-
                                                   activated K+ channel complexed Ca2+/calmodulin. Nature. 2001; 410:1120–4. [PubMed:
                                                   11323678]
                                               Schuster JE, Fu R, Siddique T, Heckman CJ. Effect prolonged riluzole exposure cultured
                                                   motoneurons mouse model ALS. J Neurophysiol. 107:484–92. [PubMed: 22013234]
                                               Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T. Differential action riluzole tetrodotoxin-
                                                   sensitive tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 1997; 282:707–14.
                                                   [PubMed: 9262334]
                                               Veldink JH, van den Berg LH, Cobben JM, Stulp RP, Jong JM, Vogels OJ, Baas F, Wokke JH,
                                                   Scheffer H. Homozygous deletion survival motor neuron 2 gene prognostic factor NIH-PA Author Manuscript




                                                   sporadic ALS. Neurology. 2001; 56:749–52. [PubMed: 11274309]
                                               Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Drug
                                                   treatment spinal muscular atrophy type  Cochrane Database Syst Rev. 2011a; 12:CD006281.
                                                   [PubMed: 22161399]
                                               Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Drug
                                                   treatment spinal muscular atrophy types II III. Cochrane Database Syst Rev. 2011b;
                                                   12:CD006282. [PubMed: 22161400]
                                               Wang YJ, Lin MW, Lin AA, Wu SN. Riluzole-induced block voltage-gated Na+ current                                                    activation BKCa channels cultured differentiated human skeletal muscle cells. Life Sci. 2008;
                                                   82:11–20. [PubMed: 18068197]
                                               Wu SN, Li HF. Characterization riluzole-induced stimulation large-conductance calcium-
                                                   activated potassium channels rat pituitary GH3 cells. J Investig Med. 1999; 47:484–95.




                                                    J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                                 Page 9


                                               Xia XM, Fakler B, Rivard  Wayman G, Johnson-Pais T, Keen JE, Ishii T, Hirschberg B, Bond CT,
                                                   Lutsenko S, Maylie J, Adelman JP. Mechanism calcium gating small-conductance calcium-
                                                   activated potassium channels. Nature. 1998; 395:503–7. [PubMed: 9774106]
NIH-PA Author Manuscript




                                               Zona C, Siniscalchi  Mercuri NB, Bernardi G. Riluzole interacts voltage-activated sodium                                                    potassium currents cultured rat cortical neurons. Neuroscience. 1998; 85:931–8. [PubMed:
                                                   9639285]
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                                    J Neurosci. Author manuscript; available PMC 2013 October 10.
                            Dimitriadi et al.                                                                                      Page 10
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                               Figure 1.
            